MGEN - MiRagen up 25% premarket on positive MRG-110 data October, 16 2019 09:22 AM Miragen Therapeutics Inc. MiRagen Therapeutics (NASDAQ:MGEN) is up 25% premarket after announcing new data from two Phase 1 clinical trials of MRG-110, a microRNA-92 inhibitor.More news on: Miragen Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...